Open-Label Adjunctive Zonisamide in the Treatment of Bipolar Disorders: A Prospective Trial
J Clin Psychiatry 2005;66(5):617-624
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The response of 62 outpatients with
DSM-IV bipolar disorders to open-label adjunctive zonisamide was
evaluated in a prospective 8-week acute trial, followed by a
48-week continuation trial, conducted from June 2001 through May
Method: During the acute trial, response to
zonisamide was assessed weekly for the first 4 weeks and every 2
weeks for the second 4 weeks with the Clinical Global Impressions
scale modified for bipolar illness (CGI-BP), the Young Mania
Rating Scale (YMRS), and the Inventory for Depressive
Symptomatology (IDS). During the continuation trial, patients
were assessed with these scales every 4 weeks. Patients' weights
and side effects were also evaluated. Outcome measures were
analyzed with repeated-measures analyses of variance.
Results: Patients with manic symptoms at study
entry (N = 34) displayed significant reductions in CGI-BP-Mania
Severity and YMRS scores in the acute and continuation (N = 19)
trials (p values < .0001 and < .001, respectively). Patients
with depressive symptoms at study entry (N = 22) showed significant
decreases in CGI-BP-Depression Severity and IDS scores in the
acute trial (p values < .001 and < .05, respectively), but
only 9 patients entered the continuation trial. Among these 9
patients, maintenance of antidepressant response was mostly
maintained. Initially euthymic patients (N = 6) showed no change in
any rating scale scores acutely, but 2 of 4 patients who entered
the continuation trial developed depressive symptoms. The 62
patients as a group showed significant weight loss in both trials
(p values < .001). However, 20 patients (32%) discontinued zonisamide for worsening mood symptoms.
Conclusion: Adjunctive zonisamide was associated
with beneficial effects on mood and body weight in some patients
with bipolar disorders, but was also associated with a high
discontinuation rate due to worsening mood symptoms.
Double-blind, placebo-controlled studies are necessary to
determine zonisamide's thymoleptic properties, if any, in bipolar